Why is Glenmark Pharma falling/rising?

As of 29-Jul, Glenmark Pharmaceuticals Ltd. is experiencing a price increase, currently at 2,159.60, reflecting a rise of 16.15 or 0.75%. The stock has shown positive momentum, gaining for the last two days with a total return of 0.92% during this period. Despite underperforming its sector by 0.66% today, Glenmark has demonstrated strong performance over the past month, with a return of 25.65%, significantly outpacing the Sensex's decline of 3.24%. The company has consistently reported positive results over the last four quarters, with a remarkable growth in profit after tax, which has likely bolstered investor confidence. Additionally, the low Debt to EBITDA ratio of 1.00 times indicates a strong ability to service debt, further enhancing its appeal to investors.
In the broader market context, Glenmark's short-term performance contrasts with the Sensex, which has declined by 1.03% over the past week. While Glenmark has outperformed the benchmark significantly over longer periods, including a 49.78% return over the last year compared to the Sensex's near flat performance, the recent drop in delivery volume by 18.52% against the five-day average suggests a potential decrease in investor participation. However, the high institutional holdings at 38.3% indicate that informed investors are backing the stock, which may provide stability and support for its price movements amidst broader market fluctuations.